Anti-CD3/CD38 Bispecific Monoclonal Antibody IGM-2644

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** An engineered bispecific, pentameric immunoglobulin M (IgM) monoclonal antibody directed against CD3, a T-cell surface antigen, and CD38, a human cell surface glycoprotein and tumor-associated antigen (TAA), with potential antineoplastic activity. IGM-2644 consists of ten CD38 binding sites and an anti-CD3epsilon single chain variable fragment (scFv) domain fused to a joining chain. Upon intravenous administration, anti-CD3/CD38 bispecific monoclonal antibody IGM-2644 targets and binds to both CD3 on T-cells and CD38 expressed on tumor cells. The resulting cross-linkage may trigger T-cell dependent cellular cytotoxicity (TDCC) and complement-dependent cytotoxicity (CDC) against CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies; its expression has been correlated with poor prognosis.

**Synonyms:** - Anti-CD3/Anti-CD38 Monoclonal Antibody IGM-2644 - Anti-CD3/CD38 Monoclonal Antibody IGM-2644 - CD38xCD3 Bispecific T Cell Engager IGM-2644 - IGM 2644 - IGM-2644 - IGM2644 - TCE IGM-2644